China National Biotec Group Company Limited

China National Biotec Group (CNBG), is a subsidiary of China National Pharmaceutical Group corporation (SINOPHARM), and has 6 subordinate biological products research institutes in Beijing, Changchun, Chengdu, Lanzhou, Shanghai and Wuhan as well as Beijing Tiantan Biological Products Co., Ltd. CNBG is a professional institute which has the longest history in vaccine and blood production research and development in China, and is the biggest biotech corporation combines research, development, production and supply in one. To date, the total assets of the group is 15.6 billion RMB, main operating revenue exceeds 5 billion RMB, is the fourth biggest vaccine manufacturer in the world. The development of CNBG represents the development history of Chinese biological products industry. CNBG developed and produced the earliest vaccine of smallpox, cholera, typhoid and rabies as well as diphtheria antitoxin etc., separated the first Penicillium strain in China. Since the establishment of P.R.C, CNBG and it's subordinate biological products research institutes take the responsibility of production of biological products for preventing, controlling and eradiating of infectious diseases, made great contribution in China's endeavor of eradiating smallpox, eliminating polio, reducing the incidence of various infectious diseases including measles, diphtheria, pertussis, epidemic encephalitis B, DCSM and hepatitis B. CNBG has strong industrialization capacity, possesses production bases in six main cities with nearly one hundred production line up to GMP standard, with the ability of manufacture more than 200 biomedicine products for prevention, treatment and diagnoses, among which there are 24 national first and second-class new medicine, 34 types of vaccines preventing 24 viruses and bacteria whereas there are 41 types of vaccines preventing 26 viruses and bacteria can be produced in China. CNBG is the biological products corporation with the most types and the largest output of vaccines and blood products in China. CNBG does its best to serve the national immunity programme, takes more than 80% production assignment of vaccines for national immunity programme. Meanwhile, with its technology advantage, contribute to research, production, facility and technology upgrade for serious infectious diseases prevention and control products, made great contribution in fighting against "SARS", disaster relief and resisting globally spread H1N1. CNBG has tremendous scientific research strength, owning a biotec experts team including academician of Chinese Academy of Engineering, more than 70 new medicine examination and approval experts of National Food and Drug Administration, more than 10 comment experts of National Science Foundation Committee, and more than 170 experts with national government allowances. CNBG is one of the first group of corporations with doctor and master degree-conferring qualification, owns 1 doctor site, 5 master sites and 5 post-doc sites. During 1989 to now, accumulatively over 700 master and 50 PHD students were trained here. CNBG has great achievement in scientific research, assumes responsibility of a lot of key projects of China 863 plan and "twelfth five" science support plan. There are more than 10 projects filled the blank in China and many production possessed intellectual property, 26 of them obtained the first and second prize of national science progress prize, more than 180 obtained provincial prize. In 2008, CNBG was named the first group of "innovative corporation" by National Scienceand Technology department, State Finance Authorities and Chinese National Federation of Trade Unions.